1. Cholesterol, CV Events, and PCSK9 Inhibitors Highlights From the AHA

2. Goal

4. Statin Intolerance

6. Serial IVUS

7. Effect on CHD Events of Lowering LDL-C

9. Percent Change in LDL-C During Treatment

10. Primary Endpoint: PAV

11. Percent of Patients Showing Regression in PAV

12. Exploratory Subgroup Baseline LDL-C Less Than 70 mg/dL

13. Safety

14. Statin Intolerance

15. Risk Factors and Workup

16. Common Drugs

17. Autoimmune Myopathy

18. Initial Management of Statin Intolerance

19. GAUSS-3 Trial

20. Who Gets the PCSK9 Inhibitor?

21. Patients With FH and Access to Care

22. FH Prevalence

23. FH Is Severely Underdiagnosed

24. The FH Foundation

25. Access to PCSK9 Inhibitors

26. Identification and Diagnosis

27. Treatment in Children and Young Adults

28. Guidance for the Use of PCSK9 Inhibitors

29. Progression and Regression of CAD

30. Atherosclerosis -- A Disease Process

32. Percent Change in LDL-C During Treatment

33. Lower Is Better

34. Abbreviations